VALENCIA, Spain, Aug. 1, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the participation of its Chairman & CEO, Frédéric Legros, in the Barclays Biotech: 1x1 Private Company Symposium on Wednesday, August 7, 2024.
This event is being held in a virtual format during which the Company will participate in one-on-one meetings with investors.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact | Investor and Media Contact |
Frédéric Legros | Amy Conrad |
Chairman and CEO | Juniper Point |
+33679495790 | +1 858-366-3243 |
SOURCE ARTHEx Biotech